We are a start-up from Houston, Texas commercializing a variety of products to elevate the standard of reproductive medicine. In 2010, our founder was an undergraduate student researcher trying to develop a new method to assess mammalian embryo health. Little did she know, this was the beginning of an invention which could help millions of infertility couples achieve their dream of having their own baby.

The technology Dr. Wells created is a noninvasive embryo selection technique which can non-subjectively assess embryo developmental potential. Unlike all other methods to assess embryo health based on morphological appearance or genetic profile, our technology measures an embryo’s buoyancy though our patent pending buoyancy chamber and analytical software. This method is non-invasive, does not harm the embryo, delivers results immediately and can be performed in any embryology lab in less than a minute.

Dr. Wells realized the multi-billion dollar value of this technology and wan...
We are a start-up from Houston, Texas commercializing a variety of products to elevate the standard of reproductive medicine. In 2010, our founder was an undergraduate student researcher trying to develop a new method to assess mammalian embryo health. Little did she know, this was the beginning of an invention which could help millions of infertility couples achieve their dream of having their own baby.

The technology Dr. Wells created is a noninvasive embryo selection technique which can non-subjectively assess embryo developmental potential. Unlike all other methods to assess embryo health based on morphological appearance or genetic profile, our technology measures an embryo’s buoyancy though our patent pending buoyancy chamber and analytical software. This method is non-invasive, does not harm the embryo, delivers results immediately and can be performed in any embryology lab in less than a minute.

Dr. Wells realized the multi-billion dollar value of this technology and wanted to take it to market. She teamed up with Greg Novak and Tracy Druce to found EMGenisys, Inc. A partnership with Greg and Tracy was a strategic move, as they are both experienced intellectual property attorneys with successful track records in biomedical commercialization, agriculture and company development. The team quickly prioritized the development of a solid IP strategy to protect the method, devices and software globally. The team then identified viable markets for the technology for use in both livestock breeding programs and in clinical human embryology. Wanting to take advantage of all opportunities, we have created distinct subsidiary companies in which one will launch the technology in livestock, validate the technologies use in cattle and further demonstrate the value. Currently, the embryo selection technology is in use with select beta customers for use on beef cattle embryos. The other subsidiary company is maintaining the right to use this technology in humans- which is what we intend to focus on in the Merck Accelerator.

In addition to the launch of our noninvasive embryo selection technology, we have developed and filed patents on a semen freezing and semen thawing technology to further improve outcomes of reproductive medicine. All of our technologies are noninvasive and provide superior results as compared to technologies in current routine use. We hope to be accepted into the Merck program so we can grow EMGenisys beyond the United States.
More information

Employees

Cara Wessels, PhD
Admin
Cara Wessels, PhD CEO I am natural go-getter. I am an entrepreneur with a scientific background seeking to revolutionize the fertility industry.